AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00768417 — intervention group
Intervention type: BEHAVIORAL
Intervention: 40 Chews
Description: Participants were required to chew 55g grams of almonds per day for four days in 11, 5 gram portions. Almonds were to be chewed 40 times before swallowing.
Study NCT01300234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF) tablets
Description: white, almond-shaped, film-coated tablets containing 300mg of TDF
Study NCT01300234 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adefovir dipivoxil (ADV) tablets
Description: white to off-white, round, biconvex tablets containing 10mg of ADV
Study NCT01849601 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: percutaneous transluminal angioplasty balloon catheter
Study NCT01271556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol
Description: 50 mcg MDI (inhalatory), once on days A and C at t=0,
Study NCT01271556 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol
Description: 50 mcg MDI (inhalatory), once on days A and C at t=0,
Study NCT01271556 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: saline infusion (0.9 per cent sodium chloride)
Description: rapid 50-minute 750-ml 0.9% saline infusion 240 minutes after inhalatory treatment on day A and B
Study NCT01271556 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: saline infusion (0.9 per cent sodium chloride)
Description: rapid 50-minute 750-ml 0.9% saline infusion 240 minutes after inhalatory treatment on day A and B
Study NCT01271556 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo, inhalatory (MDI) once
Study NCT03201588 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Formulaid
Description: Arachidonic acids (AA) Docosahexaenoic Acids(DHA) 2:1
Study NCT01799096 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sucrose
Description: Sucrose in carbonated soft drinks (4 x250ml total1800 kJ per day)
Study NCT01799096 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Aspartame
Description: Intensely sweetened soft drink (no energy content)
Study NCT04100031 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: phacoemulsification
Description: underwent standard phacoemulsification through a 2.8-mm clear corneal temporal incision and intraocular lens
Study NCT04100031 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: phacoemulsification
Description: underwent standard phacoemulsification through a 2.8-mm clear corneal temporal incision and intraocular lens
Study NCT04566471 — intervention group
Intervention type: OTHER
Intervention: prevalence/incidence
Description: It is an observational study for prevalence/incidence, no intervention provided.
Study NCT02168114 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercising
Description: This arm will only include subjects that have a confirmed diagnosis of Duchenne Muscular Dystrophy. Subjects in this arm will not undergo any exercising, and will only be imaged by Optical and Magnetic Resonance Imaging and Spectroscopy techniques at a single time point.
Study NCT02168114 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Optical and Magnetic Resonance Imaging and Spectroscopy
Description: This arm will contain subjects that are not affected by Duchenne Muscular Dystrophy. These subjects will undergo concentric exercising of one forearm, and eccentric exercising of the contralateral forearm. Two days following the exercising, subjects will undergo Optical Imaging and Magnetic Resonance Imaging and Spectroscopy.
Study NCT04957797 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: round tunnel
Description: reamed with round tunnel
Study NCT04957797 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: flat tunnel
Description: reamed with flat tunnel
Study NCT05456737 — intervention group
Intervention type: OTHER
Intervention: assessment
Description: Application of various assessment methods to determine the foot characteristics, foot posture, functional activity, balance levels and quality of life of the determined groups.
Study NCT03864822 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-Definition Transcranial Direct Current Stimulation
Description: Device uses an array of electrodes over the scalp, in contact via gel, to provide a weak electrical current.
Study NCT03864822 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: High-Definition Transcranial Direct Current Stimulation
Description: Device uses an array of electrodes over the scalp, in contact via gel, to provide a weak electrical current.
Study NCT00841334 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACTION
Description: Overweight/obese adolescents enrolled in ACTION will meet with SBHC providers over a 6 month period in one school year. SBHC providers will use Motivational Enhancement Therapy to motivate overweight/obese adolescents to adopt strategies for improving nutrition and physical activity.
Study NCT00841334 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Overweight/obese adolescents in the second arm will receive a well child check with usual anticipatory guidance.
Study NCT01845935 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Image-guided Cryoablation (FPRPR3508 IceRod® PLUS Needles)
Description: Treatment consists of a percutaneous cryoablation performed under anesthesia and imaging control.
Study NCT04130607 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conceptual teaching
Description: The present study is designed to contrast two instructional methods - explicit instruction in likelihood ratios and pretest/posttest probabilities versus implicit instruction based on presentation of multiple cases. These will be compared to a no intervention control group.
Study NCT04130607 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conceptual teaching
Description: The present study is designed to contrast two instructional methods - explicit instruction in likelihood ratios and pretest/posttest probabilities versus implicit instruction based on presentation of multiple cases. These will be compared to a no intervention control group.
Study NCT04130607 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conceptual teaching
Description: The present study is designed to contrast two instructional methods - explicit instruction in likelihood ratios and pretest/posttest probabilities versus implicit instruction based on presentation of multiple cases. These will be compared to a no intervention control group.
Study NCT04388761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allogeneic adipose derived mesenchymal stem cells
Description: Injection of Allogeneic adipose derived mesenchymal stem cells into the Kidney allograft
Study NCT00195936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Description: Single oral dose of Cinacalcet for children with Hypophosphatemic Rickets
Study NCT04265014 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Goal-directed fluid treatment
Description: Goal-directed fluid treatment for major abdominal surgery
Study NCT04265014 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Liberal Fluid Therapy
Description: Liberal Fluid Therapy for major abdominal surgery
Study NCT02608658 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical food, EnteraGam (Serum-Derived Bovine Immunoglobulin)
Description: Visit 1, screening (Day 0): At this visit, the investigators of the study will:~* Obtain demographic information, as will past medical history and medications.~* Perform a physical examination.~* Collect samples for labs~* Administer the Chronic Liver Disease Questionnaire (CLDQ)~* Perform a lactulose breath test~From Day 0 to 8 weeks: subjects will take the medical food twice daily~Visit 2, Week 4 (Day 28 +/- 3): At this visit, the investigators of the study will:~* Perform a physical examination~* Collect and record returned investigational product~* Dispense investigational product and instruct again regarding use~* Record any adverse events~Visit 3, Week 8 (Day 56 +/- 3): At this visit, the investigators of the study will:~* Perform a physical examination.~* Collect samples for labs~* Administer the Chronic Liver Disease Questionnaire (CLDQ)~* Perform a lactulose breath test
Study NCT04299165 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kaia COPD Application
Description: The study intervention consists of training sessions conducted daily by the patient via the COPD-App.
Study NCT04299165 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: The control group will also be an active control as participants receive a leaflet to convey an active lifestyle and a list of exercises to do at home.
Study NCT03564717 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Segmented three dimensionally printed transfer tray
Description: Segmented indirect bonding transfer tray
Study NCT03095079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human endostatin
Description: Cisplatin:dose was based on patient's weight and could be adjusted for weight change,75 mg/m\^2 by IV infusion separated in 3 different days Dacarbazine:250mg/m2,administered by intravenous (IV) infusion on the 1 to 5 day of each cycle~Hr-endostatin:dose based on body surface area as 15mg/m2,continuous intravenous infusion from day 1 to day 14
Study NCT00471692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivicaine
Study NCT00471692 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivicaine
Study NCT03332381 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention training technique
Description: Attention training involves modifying metacognitive control and enhancing attention flexibility so that people can refrain from responding to intrusions with extended processing.
Study NCT03332381 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindful self-compassion
Description: Self-compassion involves not avoiding painful or distressing feelings. Instead these experiences are held in awareness with kindness, understanding, and a sense of shared humanity.
Study NCT03814707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical application of 0.2% hyaluronic acid gel
Description: Topical application of 0.2% hyaluronic acid gel will be placed immediately in palatal donor site after free gingival graft harvesting
Study NCT03814707 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet rich fibrin
Description: Placement of Platelet rich fibrin in the palatal donor sie after free gingival graft harvesting and suturing by criss cross sutured then covered by periodontal pack.
Study NCT02372526 — intervention group
Intervention type: OTHER
Intervention: Mealtest: High protein 200 kcal 200 ml liquid meal consumed during 10 minutes
Study NCT02372526 — intervention group
Intervention type: OTHER
Intervention: Mealtest: High fat 200 kcal 200 ml liquid meal consumed during 10 minutes
Study NCT02372526 — intervention group
Intervention type: OTHER
Intervention: Mealtest: High carbohydrate 200 kcal 200 ml liquid meal consumed during 10 minutes
Study NCT02372526 — intervention group
Intervention type: OTHER
Intervention: Mealtest: High fat 200 kcal 200 ml liquid meal with pancreatic lipase inhibitor consumed during 10 minutes
Study NCT03983629 — intervention group
Intervention type: OTHER
Intervention: Collection of data and genetic analysis
Description: Data collected are: History of disease, medical history, family medical history, biological results, Imaging results, disease progression Genetic analysis will be performed with whole genome and whole exome sequencing
Study NCT02709213 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic
Description: Determination of pathogens and faecal calprotectin in the stools
Study NCT02128542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Sofosbuvir 400 mg tablet administered orally once daily
Study NCT02128542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study NCT03191682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRL3-ZUMAB
Description: The starting dose will be 0.3 mg/kg, administered Q2 weekly, with the subsequent dose levels being 0.9 mg/kg, 3.0 mg/kg, and 6.0 mg/kg, all administered on a Q2 weekly basis until disease progression. The investigator will monitor each subject for the occurrence of AEs. In event of infusion-related adverse events, the Investigator, in consultation with the PI, may increase the duration of the infusion over a period of up to 24 hours at their discretion. Dosing will continue in a standard 3+3 design for dose escalation.
Study NCT01815944 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.75% Ropivacaine
Study NCT01815944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.75% Ropivacaine
Study NCT01815944 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Study NCT01815944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose 5%
Study NCT01045967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: 30 mg delayed-release Capsule
Study NCT01045967 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prevacid®
Description: 30 mg delayed-release Capsule
Study NCT01863381 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tympanic membrane displacement (TMD)
Description: The CCFP Analyser has a passive mode and an active mode. When used in active mode, the device generates a tone burst that is transmitted to the ear to elicit contraction of the stapedius muscle. The passive mode requires no stimulus or sound burst.~For the lying, sitting, standing, and 10-degree head-down tilt conditions, the active mode will be used. Each condition comprises 13 stimuli of 0.3s duration.~Overnight recording of non-invasive ICP will be done using the passive mode of the CCFP device.
Study NCT01863381 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DPOAE
Description: DPOAE measurement uses a clinical acoustic probe to record the ear's response to two simultaneous tones. DPOAE measurements will be made for 13 tones. The total measurement time for each condition is 2-4 minutes.
Study NCT00675714 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stable Isotope Infusion Study
Description: 1-8 hour stable isotope infusion study to be done following each surgery. Tagged isotopes to assess uptake into blood and tissues.
Study NCT02706899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vadastuximab talirine
Description: Intravenous (IV) push every 4 weeks
Study NCT00675714 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Stable Isotope Infusion Study
Description: 1-8 hour stable isotope infusion study to be done following each surgery. Tagged isotopes to assess uptake into blood and tissues.
Study NCT00675714 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Collection of blood and tissues
Description: Blood draw with each stable isotope infusion study and weekly Tissue biopsy: skin, fat, muscle at stable isotope infusion study
Study NCT00675714 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Collection of blood and tissues
Description: Blood draw with each stable isotope infusion study and weekly Tissue biopsy: skin, fat, muscle at stable isotope infusion study
Study NCT00675714 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiology testing: Dual-energy X-ray absorptiometry (DEXA), ultrasound, MRI
Description: Testing to be done following every stable isotope infusion study to measure muscle, fat and bone tissues.
Study NCT00675714 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Radiology testing: Dual-energy X-ray absorptiometry (DEXA), ultrasound, MRI
Description: Testing to be done following every stable isotope infusion study to measure muscle, fat and bone tissues.
Study NCT00675714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humatrope
Description: Humatrope (Growth Hormone) dose:0.05mg - 0.2mg/kg/day SQ daily for up to 2 years post burn injury.
Study NCT00675714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: Ketoconazole administration (or other glucocorticoid blocker--itraconazole or fluconazole) PO daily for up to 2 years post burn injury
Study NCT00675714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxandrolone
Description: oxandrolone (or other anabolic steroid-testosterone or nandrolone) daily for up to 2 years post burn injury
Study NCT00675714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Propranolol (or other beta adrenergic blocker--metoprolol, inderol), PO administration daily for up to 2 years post burn injury.
Study NCT00675714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxandrolone and propranolol combined
Description: Daily administration of oxandrolone and propranolol to be given for up to 2 years post burn injury.
Study NCT00675714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humatrope and propranolol combined
Description: Humatrope (growth hormone) and propranolol administration daily for up to 2 years post burn injury.
Study NCT00675714 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo to be given once a day for up to two years post burn injury.
Study NCT00675714 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise--Hospital supervised intensive exercise program
Description: intensive exercise program supervised by trained personnel in the hospital environment for six up to twelve week program.
Study NCT00675714 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home exercise program
Description: Home intensive exercise program: training occurs in hospital then patient sent home to continue exercise program for six weeks and up to 12 weeks at home.
Study NCT03042117 — intervention group
Intervention type: OTHER
Intervention: periodontal probing
Description: A periodontal probe will be inserted between the tooth and the gum in the gingival sulcus and a measurement of the pocket depth will be measured by a trained dentist in all subjects
Study NCT01879917 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Study NCT01879917 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study NCT02942212 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Participants complete a computerized questionnaire to assess demographics and smoking history.
Study NCT02942212 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire
Description: Participants complete a computerized questionnaire to assess demographics and smoking history.
Study NCT02942212 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-Depth Interviews
Description: Participants take part in individual in-depth interviews discussing smoking history, attempts to quit, and suggestions for smoking cessation program. The interview should last 30-45 minutes and is audio-recorded.
Study NCT02942212 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breath Test
Description: Participants complete a breath test to assess the amount of cigarette smoke inhaled at baseline, weekly during study, and at 3 month follow up.
Study NCT02942212 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breath Test
Description: Participants complete a breath test to assess the amount of cigarette smoke inhaled at baseline, weekly during study, and at 3 month follow up.
Study NCT02942212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Patches
Description: Participants receive a 6-week supply of nicotine patches and instructions on how to use them. Patch therapy for participants who smoke >10 cigarettes/day consists of 4 weeks of 21 mg patches, 1 week of 14 mg patches, and 1 week of 7 mg patches. Patch therapy for participants who smoke 5-10 cigarettes/day consists of 4 weeks of 14 mg patches and 2 weeks of 7 mg patches.
Study NCT02942212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patches
Description: Participants receive a 6-week supply of nicotine patches and instructions on how to use them. Patch therapy for participants who smoke >10 cigarettes/day consists of 4 weeks of 21 mg patches, 1 week of 14 mg patches, and 1 week of 7 mg patches. Patch therapy for participants who smoke 5-10 cigarettes/day consists of 4 weeks of 14 mg patches and 2 weeks of 7 mg patches.
Study NCT02942212 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Advice plus Phone Counseling
Description: Participants receive brief advice to quit smoking, as well as phone counseling for support in quitting smoking (5 sessions over the course of 6 weeks) with a counselor at the Texas Quitline.
Study NCT02942212 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Advice plus Counseling Sessions
Description: Participants receive brief advice to quit smoking, as well as 5 individual, in-person smoking cessation treatment counseling sessions.
Study NCT02942212 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self Assessment Questionnaires
Description: Participants complete self assessment questionnaires the week before quitting smoking, the day that they quit, and 1, 2, and 4 weeks after quitting, and at 3 month follow up.